[go: up one dir, main page]

SI1766012T1 - Protismiselni antibakterijski postopek in spojina - Google Patents

Protismiselni antibakterijski postopek in spojina

Info

Publication number
SI1766012T1
SI1766012T1 SI200531354T SI200531354T SI1766012T1 SI 1766012 T1 SI1766012 T1 SI 1766012T1 SI 200531354 T SI200531354 T SI 200531354T SI 200531354 T SI200531354 T SI 200531354T SI 1766012 T1 SI1766012 T1 SI 1766012T1
Authority
SI
Slovenia
Prior art keywords
bases
compound
bacterial
antisense compounds
mrna
Prior art date
Application number
SI200531354T
Other languages
English (en)
Inventor
Bruce L Geller
Jesse D Deere
Patrick L Iversen
Original Assignee
Avi Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avi Biopharma Inc filed Critical Avi Biopharma Inc
Publication of SI1766012T1 publication Critical patent/SI1766012T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65613Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system (X = CH2, O, S, NH) optionally with an additional double bond and/or substituents, e.g. cephalosporins and analogs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/314Phosphoramidates
    • C12N2310/3145Phosphoramidates with the nitrogen in 3' or 5'-position
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3233Morpholino-type ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
SI200531354T 2004-07-02 2005-07-01 Protismiselni antibakterijski postopek in spojina SI1766012T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58511204P 2004-07-02 2004-07-02
PCT/US2005/023553 WO2006085973A2 (en) 2004-07-02 2005-07-01 Antisense antibacterial method and compound
EP05857499A EP1766012B1 (en) 2004-07-02 2005-07-01 Antisense antibacterial method and compound

Publications (1)

Publication Number Publication Date
SI1766012T1 true SI1766012T1 (sl) 2011-10-28

Family

ID=36686070

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531354T SI1766012T1 (sl) 2004-07-02 2005-07-01 Protismiselni antibakterijski postopek in spojina

Country Status (12)

Country Link
US (4) US8314072B2 (sl)
EP (2) EP1766012B1 (sl)
AT (1) ATE510914T1 (sl)
AU (1) AU2005327188C8 (sl)
CA (2) CA2875436A1 (sl)
CY (1) CY1111765T1 (sl)
DK (1) DK1766012T3 (sl)
ES (1) ES2367289T3 (sl)
PL (1) PL1766012T3 (sl)
PT (1) PT1766012E (sl)
SI (1) SI1766012T1 (sl)
WO (1) WO2006085973A2 (sl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171044A1 (en) * 2003-12-24 2005-08-04 Stein David A. Oligonucleotide compound and method for treating nidovirus infections
CA2875436A1 (en) 2004-07-02 2006-08-17 Sarepta Therapeutics, Inc. Antisense antibacterial method and compound
US7790694B2 (en) * 2005-07-13 2010-09-07 Avi Biopharma Inc. Antisense antibacterial method and compound
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2007009094A2 (en) * 2005-07-13 2007-01-18 Avi Biopharma, Inc. Antisense antibacterial method and compound
WO2007136989A2 (en) * 2006-05-05 2007-11-29 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of dgat2
ES2645410T3 (es) * 2006-05-10 2017-12-05 Sarepta Therapeutics, Inc. Análogos de oligonucleótidos que tienen enlaces intersubunitarios catiónicos
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
JP2010510807A (ja) * 2006-11-27 2010-04-08 アイシス ファーマシューティカルズ, インコーポレーテッド 高コレステロール血症を治療するための方法
US9050373B2 (en) 2010-05-13 2015-06-09 The Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
EP2576574A2 (en) 2010-05-28 2013-04-10 Sarepta Therapeutics, Inc. Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
JP6023705B2 (ja) * 2010-06-23 2016-11-09 カッパーアールエヌエー,インコーポレイテッド ナトリウムチャネル、電位依存性、αサブユニット(SCNA)に対する天然アンチセンス転写物の阻害によるSCNA関連疾患の治療
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
US20120122769A1 (en) * 2010-11-12 2012-05-17 Avi Biopharma, Inc. Antisense antibacterial compounds and methods
WO2012109296A1 (en) 2011-02-08 2012-08-16 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Antisense oligonucleotides
CN108864192A (zh) 2011-11-18 2018-11-23 萨勒普塔医疗公司 功能改性的寡核苷酸及其亚单元
US9920085B2 (en) 2012-03-20 2018-03-20 Sarepta Therapeutics, Inc. Boronic acid conjugates of oligonucleotide analogues
JP6901966B2 (ja) 2014-05-16 2021-07-14 オレゴン ステート ユニバーシティ アンチセンス抗菌化合物および方法
JP6687542B2 (ja) 2014-05-19 2020-04-22 オレゴン ステート ユニバーシティ アンチセンス抗菌化合物および方法
WO2016003816A1 (en) * 2014-07-01 2016-01-07 The University Of North Carolina At Chapel Hill Small molecules that enhance the activity of oligonucleotides
AU2015372560B2 (en) 2014-12-31 2021-12-02 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
WO2017112885A1 (en) 2015-12-23 2017-06-29 David Greenberg Antisense antibacterial compounds and methods

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521063A (en) * 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5185444A (en) * 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5506337A (en) * 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5217866A (en) * 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
DE3687030T2 (de) * 1985-03-15 1993-03-11 Eugene Stirchak Stereoregulare polynukleotiden bindende polymere.
US5749847A (en) * 1988-01-21 1998-05-12 Massachusetts Institute Of Technology Delivery of nucleotides into organisms by electroporation
ATE312834T1 (de) 1989-12-20 2005-12-15 Avi Biopharma Inc Ungeladene, auf morpholin basierende polymere mit chiralen, phosphor enthaltenden brücken zwischen den untereinheiten
US5852188A (en) * 1990-01-11 1998-12-22 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
BR9106747A (pt) 1990-08-14 1993-07-20 Isis Pharmaceuticals Inc Oligonucleotideo ou analogo de oligonucleotideo e processo para tratamento de um animal suspeito de estar infectado por virus da influenza
JPH07501204A (ja) 1991-06-28 1995-02-09 マサチューセッツ インスティテュート オブ テクノロジー 局所的オリゴヌクレオチド療法
US6030954A (en) * 1991-09-05 2000-02-29 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
US5821052A (en) 1992-04-16 1998-10-13 University Of Medicine And Dentistry Of New Jersey Control of the synthesis of proteins by anitisense RNA-tRNA complex
US6174868B1 (en) 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US6060456A (en) * 1993-11-16 2000-05-09 Genta Incorporated Chimeric oligonucleoside compounds
US5479847A (en) * 1994-11-07 1996-01-02 Marlen Research Corporation Dual-piston pump apparatus
GB9505438D0 (en) 1995-03-17 1995-05-03 Sod Conseils Rech Applic Antisense oligonucleotides
GB9510718D0 (en) * 1995-05-26 1995-07-19 Sod Conseils Rech Applic Antisense oligonucleotides
JP2000509394A (ja) 1996-05-01 2000-07-25 アンティバイラルズ インコーポレイテッド 細胞膜を横切って物質を輸送するためのポリペプチド結合体
AU3811897A (en) 1996-07-24 1998-02-10 Oglios Therapeutics, Inc. Antisense oligonucleotides as antibacterial agents
CA2278924A1 (en) 1997-01-24 1998-07-30 Avi Biopharma, Inc. Method and conjugate for treating h. pylori infection
AU734827B2 (en) * 1997-05-21 2001-06-21 Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
US6204019B1 (en) 1997-06-04 2001-03-20 Smithkline Beecham Corporation Sec A2 from Streptococcus pneumoniae
US6610539B1 (en) 1997-07-10 2003-08-26 Genesense Technologies, Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
EP0894857A3 (en) 1997-08-01 2001-09-26 Smithkline Beecham Corporation SecA gene from Streptococcus pneumoniae
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6228579B1 (en) * 1997-11-14 2001-05-08 San Diego State University Foundation Method for identifying microbial proliferation genes
US6548651B1 (en) * 1998-11-11 2003-04-15 Pantheco A/S Modified peptide nucleic acid (PNA) molecules
US7094765B1 (en) * 1999-01-29 2006-08-22 Avi Biopharma, Inc. Antisense restenosis composition and method
EP1173561A2 (en) * 1999-01-29 2002-01-23 Avi Biopharma, Inc. Non-invasive method for detecting target rna
US6521438B1 (en) * 1999-11-05 2003-02-18 North Carolina State University Chemoreceptors in plant parasitic nematodes
US20030095953A1 (en) * 1999-11-12 2003-05-22 Myles C. Cabot Methods of reversing drug resistance in cancer cells
US6677153B2 (en) * 1999-11-29 2004-01-13 Avi Biopharma, Inc. Antisense antibacterial method and composition
EP1248813A2 (en) * 2000-01-04 2002-10-16 Avi Biopharma, Inc. Antisense antibacterial cell division composition and method
US7833992B2 (en) * 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US20040072743A1 (en) * 2000-04-06 2004-04-15 Christensen Jeppe Viggo Pharmaceutical composition of modified pna molecules
JP2003533986A (ja) * 2000-05-04 2003-11-18 エイブイアイ バイオファーマ, インコーポレイテッド スプライス領域アンチセンス組成物および方法
EP1301525B1 (en) * 2000-07-06 2015-09-02 Sarepta Therapeutics, Inc. Transforming growth factor beta (tgf-beta) blocking agent-treated stem cell composition and method
WO2002034771A2 (en) * 2000-10-27 2002-05-02 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
WO2002079467A2 (en) * 2001-03-29 2002-10-10 Københavns Universitet Antibiotic-free bacterial strain selection with antisense molecules
AU2002317437A1 (en) * 2001-05-18 2002-12-03 Cureon A/S Therapeutic uses of lna-modified oligonucleotides in infectious diseases
US20030224353A1 (en) * 2001-10-16 2003-12-04 Stein David A. Antisense antiviral agent and method for treating ssRNA viral infection
US6828105B2 (en) * 2001-10-16 2004-12-07 Avi Biopharma, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
WO2004041854A2 (en) * 2002-11-05 2004-05-21 Affinium Pharmaceuticals, Inc. Essential novel bacterial polypeptides
EP2351844B1 (en) 2003-04-29 2014-06-11 Sarepta Therapeutics, Inc. Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
AU2004242249A1 (en) * 2003-05-23 2004-12-02 Epfl-Ecole Polytechnique Federale De Lausanne Methods for protein labeling based on acyl carrier protein
ATE491791T1 (de) 2003-08-05 2011-01-15 Avi Biopharma Inc Oligonukleotidanalog und verfahren zur behandlung von flavivirusinfektionen
US7402574B2 (en) 2004-03-12 2008-07-22 Avi Biopharma, Inc. Antisense composition and method for treating cancer
CA2875436A1 (en) 2004-07-02 2006-08-17 Sarepta Therapeutics, Inc. Antisense antibacterial method and compound
US8357664B2 (en) * 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US7524829B2 (en) 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
US7790694B2 (en) * 2005-07-13 2010-09-07 Avi Biopharma Inc. Antisense antibacterial method and compound
US8067571B2 (en) * 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2007009094A2 (en) 2005-07-13 2007-01-18 Avi Biopharma, Inc. Antisense antibacterial method and compound
ES2645410T3 (es) 2006-05-10 2017-12-05 Sarepta Therapeutics, Inc. Análogos de oligonucleótidos que tienen enlaces intersubunitarios catiónicos
US10100305B2 (en) 2011-07-15 2018-10-16 Sarepta Therapeutics, Inc. Methods and compositions for manipulating translation of protein isoforms from alternative initiation of start sites

Also Published As

Publication number Publication date
WO2006085973A2 (en) 2006-08-17
US7625873B2 (en) 2009-12-01
US20070049542A1 (en) 2007-03-01
CA2571593A1 (en) 2006-08-17
US20130289091A1 (en) 2013-10-31
US20070021362A1 (en) 2007-01-25
US20100137408A1 (en) 2010-06-03
EP2351839A3 (en) 2011-10-05
CA2571593C (en) 2015-04-21
AU2005327188C9 (en) 2011-09-22
CA2875436A1 (en) 2006-08-17
PT1766012E (pt) 2011-09-05
WO2006085973A3 (en) 2007-04-12
EP1766012A2 (en) 2007-03-28
US9534220B2 (en) 2017-01-03
PL1766012T3 (pl) 2011-11-30
AU2005327188C1 (en) 2011-07-07
EP1766012B1 (en) 2011-05-25
ES2367289T3 (es) 2011-11-02
US8314072B2 (en) 2012-11-20
CY1111765T1 (el) 2015-10-07
DK1766012T3 (da) 2011-09-19
ATE510914T1 (de) 2011-06-15
EP2351839A2 (en) 2011-08-03
AU2005327188C8 (en) 2011-09-22
AU2005327188B2 (en) 2011-03-17
AU2005327188A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
CY1111765T1 (el) Αντινοηματικη αντιβακτηριακη μεθοδος και ενωση
DE69934242D1 (de) Polyketid synthase enzyme und rekombinante dna konstrukte dafür, zur herstellung von mit fk-506 und fk-520 verwandten verbindungen
EP4527459A3 (en) Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
WO2007051045A3 (en) Compositions and methods for inhibiting expression of huntingtin gene
WO2007056326A3 (en) Compositions and methods for inhibiting expression of nav1.8 gene
MX2007002382A (es) Producci??n de anticuerpos anti-amiloides beta.
PL1776455T3 (pl) Enzym lipolityczny, jego zastosowania w przemyśle spożywczym
EP1569695A4 (en) ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
AU2001290706A1 (en) Antisense modulation of clusterin expression
WO2007009094A3 (en) Antisense antibacterial method and compound
WO2004065580A3 (en) Mesecnhymal stem cells as a vehicle for ion channel transfer in syncytial structures
WO2004011610A3 (en) Antisense modulation of polo-like kinase expression
WO2003097662A8 (en) Antisense modulation of apolipoprotein b expression
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
WO2009047992A1 (ja) Udp-グルクロン酸転移酵素およびそれをコードするポリヌクレオチド
WO2004016754A3 (en) ANTISENSE MODULATION OF Nav1.3 EXPRESSION
WO2005058945A3 (de) Genvarianten die für proteine aus dem stoffwechselweg von feinchemikalien kodieren
WO2007137220A3 (en) Compositions and methods for inhibiting expression of ikk-b gene
ATE514718T1 (de) Peptabody für krebsbehandlung
EP1248633A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF GLYCOGEN SYNTHASE KINASE 3 BETA
WO2007093848A3 (en) Crystalline enoyl-(acyl-carrier-protein) reductase from heliobacter pylori
WO2002101068A3 (en) Process for the preparation of d-pantothenic acid and/or salts thereof
WO2003023044A3 (en) Process for the production of l-amino acids using coryneform bacteria
WO2004016749A3 (en) Antisense modulation of acyl-coa synthetase 1 expression
EP1813289A4 (en) MEDICINAL COMPOSITION FOR THE TREATMENT OF CANCER OR DIABETES